

# cobas<sup>®</sup> 4800 BRAF V600 Mutation Test



FOR *IN VITRO* DIAGNOSTIC USE.

|                                                 |               |          |                  |
|-------------------------------------------------|---------------|----------|------------------|
| cobas <sup>®</sup> DNA Sample Preparation Kit   | <b>DNA SP</b> | 24 Tests | P/N: 05985536190 |
| cobas <sup>®</sup> 4800 BRAF V600 Mutation Test | <b>BRAF</b>   | 24 Tests | P/N: 05985579190 |

**NOTICE:** The purchase of this product allows the purchaser to use it for amplification and detection of nucleic acid sequences by polymerase chain reaction (PCR) and related processes for human *in vitro* diagnostics for the specific intended use stated in this Package Insert. No general patent or other license of any kind other than this specific right of use from purchase is granted hereby outside of the indications for use stated here.

## TABLE OF CONTENTS

|                                                                                            |    |
|--------------------------------------------------------------------------------------------|----|
| TABLE OF CONTENTS.....                                                                     | 1  |
| INTENDED USE.....                                                                          | 3  |
| SUMMARY AND EXPLANATION OF THE TEST.....                                                   | 3  |
| PRINCIPLES OF THE PROCEDURE.....                                                           | 3  |
| Specimen Preparation.....                                                                  | 3  |
| PCR Amplification and Detection.....                                                       | 4  |
| Target Selection.....                                                                      | 4  |
| Target Amplification.....                                                                  | 4  |
| Automated Real-time Detection.....                                                         | 4  |
| Selective Amplification.....                                                               | 4  |
| REAGENTS.....                                                                              | 4  |
| WARNINGS AND PRECAUTIONS.....                                                              | 7  |
| STORAGE AND HANDLING REQUIREMENTS.....                                                     | 8  |
| MATERIALS PROVIDED.....                                                                    | 8  |
| MATERIALS REQUIRED BUT NOT PROVIDED.....                                                   | 9  |
| Instrumentation and Software.....                                                          | 9  |
| SPECIMEN COLLECTION, TRANSPORT AND STORAGE.....                                            | 10 |
| A. Specimen Collection.....                                                                | 10 |
| B. Specimen Transport.....                                                                 | 10 |
| C. Specimen Storage.....                                                                   | 10 |
| INSTRUCTIONS FOR USE.....                                                                  | 10 |
| Run Size.....                                                                              | 10 |
| Workflow.....                                                                              | 10 |
| Reagent Preparation.....                                                                   | 11 |
| Deparaffinization of FFPE Sections Mounted on Slides.....                                  | 11 |
| Deparaffinization of FFPE Sections not Mounted on Slides.....                              | 11 |
| DNA Isolation.....                                                                         | 12 |
| DNA Quantitation.....                                                                      | 13 |
| AMPLIFICATION AND DETECTION.....                                                           | 13 |
| Instrument Set-Up.....                                                                     | 13 |
| Test Order Set-Up.....                                                                     | 13 |
| Dilution Calculation of Specimen DNA Stock at Concentrations from 5 ng/μL to 35 ng/μL..... | 14 |
| Dilution Calculation of Specimen DNA Stock at Concentrations >35 ng/μL.....                | 14 |

|                                                        |    |
|--------------------------------------------------------|----|
| Specimen Dilution.....                                 | 14 |
| Preparation of Working Master Mix (MMX).....           | 15 |
| Addition of Controls and Specimens.....                | 15 |
| Starting PCR.....                                      | 16 |
| INTERPRETATION OF RESULTS.....                         | 16 |
| Retesting of Specimens with Invalid Results.....       | 17 |
| QUALITY CONTROL.....                                   | 17 |
| BRAF Mutant Control.....                               | 17 |
| BRAF Wild-Type Control.....                            | 17 |
| PROCEDURAL PRECAUTIONS.....                            | 18 |
| PROCEDURAL LIMITATIONS.....                            | 18 |
| NON-CLINICAL PERFORMANCE EVALUATION.....               | 18 |
| Analytical Sensitivity - Limit of Blank (LoB).....     | 18 |
| Analytical Sensitivity - Limit of Detection (LoD)..... | 19 |
| Analytical Sensitivity Using Specimen Blends.....      | 19 |
| Analytical Sensitivity Using FFPET Specimens.....      | 19 |
| Analytical Sensitivity Using Cell Line Blend.....      | 19 |
| Minimal Tumor Content.....                             | 20 |
| Cross-Reactivity.....                                  | 21 |
| BRAF Non-V600E Melanoma FFPET Specimens.....           | 22 |
| BRAF Non-V600E Plasmids.....                           | 22 |
| Plasmids of BRAF Homologs.....                         | 23 |
| Skin-related Microorganisms.....                       | 23 |
| Interference.....                                      | 23 |
| Reproducibility.....                                   | 25 |
| Vemurafenib Clinical Efficacy.....                     | 28 |
| REFERENCES.....                                        | 30 |

## INTENDED USE

The **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test is an in vitro diagnostic device intended for the qualitative detection of BRAF V600E mutation in DNA extracted from formalin-fixed, paraffin-embedded human melanoma tissue. The **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test is a real-time PCR test on the **cobas**<sup>®</sup> 4800 System, and is intended to be used as an aid in selecting melanoma patients for treatment with the targeted therapies listed in the table below, in accordance with the approved therapeutic product labeling:

| Therapeutic                                                                                  | Therapeutic Indication | Test Result        |
|----------------------------------------------------------------------------------------------|------------------------|--------------------|
| ZELBORAF <sup>®</sup> (vemurafenib)                                                          | BRAF V600E             | Mutation Detected  |
| COTELLIC <sup>®</sup> (cobimetinib), in combination with ZELBORAF <sup>®</sup> (vemurafenib) | BRAF V600E or V600K*   | Mutation Detected* |

\*Due to cross-reactivity by the **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test, the clinical trial for cobimetinib, in combination with vemurafenib, included some patients whose tumor carried the BRAF V600K mutation.

## SUMMARY AND EXPLANATION OF THE TEST

Activating mutations of the proto-oncogene BRAF occur in many human cancers, including malignant melanoma, colorectal cancer, ovarian cancer, and thyroid cancer.<sup>1,2</sup> BRAF mutations have been identified in 40%-60% of malignant melanomas.<sup>3</sup> Mutations are also common in benign nevi,<sup>4</sup> suggesting that such mutations are a very early event. The discovery of such somatic mutations in the BRAF gene in melanoma and other human tumors has helped to elucidate the central role of the BRAF kinase in signaling pathways that control cellular proliferation, differentiation and cell death. In normal cells, BRAF is part of a highly regulated signaling pathway that mediates the effects of growth factor receptors (such as EGFR) through RAS, RAF, MEK and ERK. Oncogenic mutations in BRAF result in a gain of kinase function, rendering the RAF-MEK-ERK pathway constitutively active in the absence of the typical growth factors.

The majority of BRAF mutations in melanoma and other human tumors occur in codon 600.<sup>5</sup> The predominant mutation at codon 600 is the V600E mutation (GTG>GAG). A number of dinucleotide mutations affecting codon 600 [V600K (GTG>AAG), V600R (GTG>AGG) V600E2 (GTG>GAA), and V600D (GTG>GAT)] have also been observed less commonly, primarily in melanoma and rarely in other tumors, such as colorectal cancer. The **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test is a real-time PCR assay designed to detect the presence of the V600E (T1799A) mutation. The **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test is used as a companion diagnostic test for vemurafenib, a compound which inhibits the mutant V600E version of BRAF. Clinical trials of vemurafenib in patients with advanced melanoma have shown that patients with a V600E-mutant tumor are likely to experience clinical benefit from the compound.<sup>6,7</sup> Subsequently, a clinical trial of cobimetinib, in combination with vemurafenib, in patients with advanced melanoma has shown that patients with either a V600E- or V600K-mutant tumor are likely to experience clinical benefit from this therapy.<sup>8,9</sup> V600K is present in approximately 10-15% of melanoma specimens with BRAF V600 mutations.<sup>10</sup>

## PRINCIPLES OF THE PROCEDURE

The **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test (**cobas**<sup>®</sup> BRAF Test) is based on two processes: (1) manual specimen preparation to obtain genomic DNA from formalin-fixed, paraffin-embedded tissue (FFPET); (2) PCR amplification and detection target DNA using a complementary primer pair and two oligonucleotide probes labeled with different fluorescent dyes. One probe is designed to detect the wild-type BRAF V600 sequence and one is designed to detect the V600E mutation sequence. Two external run controls are provided and the wild-type allele serves as an internal, full process control.

### Specimen Preparation

FFPET specimens are processed and genomic DNA isolated using the **cobas**<sup>®</sup> DNA Sample Preparation Kit, a manual specimen preparation based on nucleic acid binding to glass fibers. A deparaffinized 5-µm section of an FFPET specimen is lysed by incubation at an elevated temperature with a protease and chaotropic lysis/binding buffer that releases nucleic acids and protects the released genomic DNA from DNases. Subsequently, isopropanol is added to the lysis mixture that is then centrifuged through a column with a glass fiber filter insert. During centrifugation, the genomic DNA is bound to the surface of the glass fiber filter. Unbound substances, such as salts, proteins and other cellular impurities, are removed by centrifugation. The adsorbed nucleic acids are washed and then eluted with an aqueous solution. The amount of genomic DNA is spectrophotometrically determined and adjusted to a fixed concentration to be added to the amplification and detection mixture. The target DNA is then amplified and detected on the **cobas z** 480 analyzer using the amplification and detection reagents provided in the **cobas**<sup>®</sup> BRAF Test kit.

## Target Selection

The **cobas®** BRAF Test uses primers that define a 116-base pair sequence of human genomic DNA containing the BRAF codon 600 site in exon 15. The entire BRAF gene is not amplified. The **cobas®** BRAF Test is designed to detect the nucleotide (T1799A) change in the BRAF gene which results in a valine-to-glutamic acid substitution at codon 600 (V600E). BRAF wild-type and mutant DNA target-specific, fluorescent dye-labeled TaqMan probes bind to the wild-type and mutant sequences, respectively. The wild-type and mutant sequences are detected using a dedicated optical channel for each sequence.

## Target Amplification

Thermus species Z05 DNA polymerase is utilized for target amplification. First, the PCR reaction mixture is heated to denature the genomic DNA and expose the primer target sequences. As the mixture cools, the upstream and downstream primers anneal to the target DNA sequences. The Z05 DNA Polymerase, in the presence of divalent metal ion and excess dNTPs, extends each annealed primer, thus synthesizing a second DNA strand. This completes the first cycle of PCR, yielding a double-stranded DNA copy of the targeted 116-basepair region of the BRAF gene. This process is repeated for a number of cycles, with each cycle effectively doubling the amount of amplicon DNA. Amplification occurs only in the region of the BRAF gene between the primers.

## Automated Real-time Detection

The **cobas®** BRAF Test utilizes real-time PCR technology. Each target-specific, oligonucleotide probe in the reaction is labeled with a fluorescent dye that serves as a reporter, and with a quencher molecule that absorbs (quenches) fluorescent emissions from the reporter dye within an intact probe. During each cycle of amplification, probe complementary to the single-stranded DNA sequence in the amplicon binds and is subsequently cleaved by the 5' to 3' nuclease activity of the Z05 DNA Polymerase. Once the reporter dye is separated from the quencher by this nuclease activity, fluorescence of a characteristic wavelength can be measured when the reporter dye is excited by the appropriate spectrum of light. Two different reporter dyes are used to label the target-specific BRAF wild-type (WT) probe and the BRAF V600E mutation probe. Amplification of the two BRAF sequences can be detected independently in a single reaction well by measuring fluorescence at the two characteristic wavelengths in dedicated optical channels.

## Selective Amplification

Selective amplification of target nucleic acid from the specimen is achieved in the **cobas®** BRAF Test by the use of AmpErase (uracil-N-glycosylase) enzyme and deoxyuridine triphosphate (dUTP).<sup>11</sup> The AmpErase enzyme recognizes and catalyzes the destruction of DNA strands containing deoxyuridine, but not DNA containing thymidine. Deoxyuridine is not present in naturally occurring DNA, but is always present in amplicon due to the use of dUTP as one of the nucleotide triphosphates in the Reaction Mix reagent; therefore, only amplicon contains deoxyuridine. Deoxyuridine renders contaminating amplicon susceptible to destruction by AmpErase enzyme prior to amplification of the target DNA. The AmpErase enzyme, which is included in the Reaction Mix reagent, catalyzes the cleavage of deoxyuridine-containing DNA at the deoxyuridine residues by opening the deoxyribose chain at the C1-position. When heated in the first thermal cycling step at alkaline pH, the amplicon DNA chain breaks at the position of the deoxyuridine, thereby rendering the DNA non-amplifiable. The AmpErase enzyme is inactive at temperatures above 55°C, i.e., throughout the thermal cycling steps, and therefore does not destroy target amplicon.

## REAGENTS

| <b>cobas® DNA Sample Preparation Kit (DNA SP)</b> |                                                                                                |                         |                                              |
|---------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------|
| <b>24 Tests (P/N: 05985536190)</b>                |                                                                                                |                         |                                              |
| <b>Kit components</b>                             | <b>Reagent ingredients</b>                                                                     | <b>Quantity per kit</b> | <b>Safety symbol and warning<sup>a</sup></b> |
| <b>DNA TLB<br/>(DNA Tissue<br/>Lysis Buffer)</b>  | Tris-HCl buffer<br>Potassium chloride<br>0.04% EDTA<br>0.1% Triton X-100<br>0.09% Sodium azide | 1 x 10 mL               | N/A                                          |

| cobas® DNA Sample Preparation Kit (DNA SP) |                                            |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------|--------------------------------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 24 Tests (P/N: 05985536190)                |                                            |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Kit components                             | Reagent ingredients                        | Quantity per kit | Safety symbol and warning <sup>a</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PK<br>(Proteinase K)                       | Proteinase K<br>(lyophilized) <sup>b</sup> | 1 x 100 mg       |  <p><b>DANGER</b></p> <p>H315: Causes skin irritation.<br/> H317: May cause an allergic skin reaction.<br/> H319: Causes serious eye irritation.<br/> H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.<br/> H335: May cause respiratory irritation.</p> <p>P261: Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.<br/> P280: Wear protective gloves/ eye protection/ face protection.<br/> P284: Wear respiratory protection.<br/> P304 + P340 + P312: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.<br/> P333 + P313: If skin irritation or rash occurs: Get medical advice/ attention.<br/> P342 + P311: If experiencing respiratory symptoms: Call a POISON CENTER/doctor.</p> |

| cobas® DNA Sample Preparation Kit (DNA SP)<br>24 Tests (P/N: 05985536190) |                                                                                                                   |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kit components                                                            | Reagent ingredients                                                                                               | Quantity per kit | Safety symbol and warning <sup>a</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>DNA PBB<br/>(DNA Paraffin<br/>Binding Buffer)</b>                      | Tris-HCl buffer<br>49.6% Guanidine<br>hydrochloride <sup>b</sup><br>0.05% Urea<br>17.3% Triton X-100 <sup>b</sup> | 1 x 10 mL        |  <p><b>DANGER</b></p> <p>H302: Harmful if swallowed.<br/> H315: Causes skin irritation.<br/> H318: Causes serious eye damage.<br/> P264: Wash skin thoroughly after handling.<br/> P270: Do not eat, drink or smoke when using this product.<br/> P280: Wear protective gloves/ eye protection/ face protection.<br/> P301 + P312 + P330: IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.<br/> P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.<br/> P501: Dispose of contents/ container to an approved waste disposal plant.</p> |

| cobas® DNA Sample Preparation Kit (DNA SP) |                                                                |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------|----------------------------------------------------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 24 Tests (P/N: 05985536190)                |                                                                |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Kit components                             | Reagent ingredients                                            | Quantity per kit | Safety symbol and warning <sup>a</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>WB I<br/>(DNA Wash<br/>Buffer I)</b>    | Tris-HCl buffer<br>64% Guanidine<br>hydrochloride <sup>b</sup> | 1 x 25 mL        |  <p><b>WARNING</b></p> <p>H302 + H332: Harmful if swallowed or if inhaled.</p> <p>H315: Causes skin irritation.</p> <p>H319: Causes serious eye irritation.</p> <p>P261: Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.</p> <p>P264: Wash skin thoroughly after handling.</p> <p>P280: Wear protective gloves/ eye protection/ face protection.</p> <p>P304 + P340 + P312: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.</p> <p>P337 + P313: If eye irritation persists: Get medical advice/ attention.</p> <p>P501: Dispose of contents/ container to an approved waste disposal plant.</p> |
| <b>WB II<br/>(DNA Wash<br/>Buffer II)</b>  | Tris-HCl buffer<br>Sodium chloride                             | 1 x 12.5 mL      | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>DNA EB<br/>(DNA Elution<br/>Buffer)</b> | Tris-HCl buffer<br>0.09% Sodium azide                          | 1 x 6 mL         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>FT<br/>(Filter tubes<br/>with caps)</b> | N/A                                                            | 1 x 25 pcs       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>CT<br/>(Collection<br/>Tubes)</b>       | N/A                                                            | 3 x 25 pcs       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<sup>a</sup> Product safety labeling primarily follows EU GHS guidance

<sup>b</sup> Hazardous substance

| cobas® 4800 BRAF V600 Mutation Test (BRAF)<br>24 Tests (P/N: 05985579190) |                                                                                                                                                                                                                                                                                                          |                  |                           |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------|
| Kit components                                                            | Reagent ingredients                                                                                                                                                                                                                                                                                      | Quantity per kit | Safety symbol and warning |
| <b>RXNMIX<br/>(Reaction Mix)</b>                                          | Tricine buffer<br>Potassium acetate<br>Potassium hydroxide<br>Glycerol<br>Tween 20<br>EDTA<br>5% Dimethyl sulfoxide<br>< 0.09% dNTPs<br>< 0.10% Z05 DNA polymerase (microbial)<br>< 0.10% AmpErase (uracil-N-glycosylase) enzyme (microbial)<br><0.003%<br>Oligonucleotide aptamer<br>0.08% Sodium azide | 3 x 0.16 mL      | N/A                       |
| <b>MGAC<br/>(Magnesium acetate)</b>                                       | Magnesium Acetate<br>0.09% Sodium azide                                                                                                                                                                                                                                                                  | 3 x 0.15 mL      | N/A                       |
| <b>BRAF OM<br/>(BRAF Oligo Mix)</b>                                       | Tris-HCl buffer<br>EDTA<br>0.09% Sodium azide<br>Poly rA RNA (synthetic)<br>< 0.01% Upstream and downstream BRAF primers<br>< 0.01% Fluorescent-labeled BRAF probes                                                                                                                                      | 3 x 0.13 mL      | N/A                       |
| <b>BRAF MUT<br/>(BRAF Mutant Control)</b>                                 | Tris-HCl buffer<br>EDTA<br>Poly rA RNA (synthetic)<br>0.05% Sodium azide<br>< 0.001% plasmid DNA (microbial) containing BRAF mutant sequence<br>< 0.001% plasmid DNA (microbial) containing BRAF wild-type sequence                                                                                      | 2 x 0.13 mL      | N/A                       |
| <b>BRAF WT<br/>(BRAF Wild-Type Control)</b>                               | Tris-HCl buffer<br>EDTA<br>Poly rA RNA (synthetic)<br>0.05% Sodium azide<br>< 0.001% plasmid DNA (microbial) containing BRAF wild-type sequence                                                                                                                                                          | 2 x 0.13 mL      | N/A                       |
| <b>DNA SD<br/>(DNA Specimen Diluent)</b>                                  | Tris-HCl buffer<br>0.09% Sodium azide                                                                                                                                                                                                                                                                    | 2 x 1 mL         | N/A                       |

## WARNINGS AND PRECAUTIONS

- A. FOR *IN VITRO* DIAGNOSTIC USE.
- B. This test is for use with formalin-fixed, paraffin-embedded tissue specimens.
- C. Do not pipette by mouth.
- D. Do not eat, drink or smoke in laboratory work areas.
- E. Avoid microbial and DNA contamination of reagents.
- F. Dispose of unused reagents and waste in accordance with country, federal, state and local regulations.
- G. Do not use kits after their expiration dates.
- H. Do not pool reagents from different kits or lots.
- I. Safety Data Sheets (SDS) are available on request from your local Roche office.
- J. Gloves must be worn and must be changed between handling specimens and **cobas**<sup>®</sup> 4800 reagents to prevent contamination.
- K. To avoid contamination of the working Master Mix with DNA specimens, Amplification and Detection should be performed in an area separated from DNA Isolation. The amplification and detection work area should be thoroughly cleaned before working Master Mix preparation. For proper cleaning, all surfaces including racks and pipettors should be thoroughly wiped with 0.5% Sodium hypochlorite\* solution followed by wiping with a 70% ethanol solution.
- L. **DNA PBB, WB I and WB II** contain guanidine hydrochloride. If liquid containing this buffer is spilled, clean with suitable laboratory detergent and water. If a spill occurs with potentially infectious agents, clean the affected area first with laboratory detergent and water, and then with 0.5% sodium hypochlorite. If spills occur on the **cobas z 480** analyzer, follow the instructions in the **cobas**<sup>®</sup> 4800 System Operator's Manual.  
  
**\*Note: Commercial liquid household bleach typically contains sodium hypochlorite at a concentration of 5.25%. A 1:10 dilution of household bleach will produce a 0.5% sodium hypochlorite solution.**
- M. Specimens should be handled as infectious using safe laboratory procedures such as those outlined in *Biosafety in Microbiological and Biomedical Laboratories*<sup>12</sup> and in the CLSI Document M29-A4.<sup>13</sup>
- N. **DNA TLB** and **DNA PBB** contain Triton X-100, an irritant to mucous membranes. Avoid contact with eyes, skin and mucous membranes.
- O. **DNA TLB, DNA PBB, DNA EB, RXNMIX, MGAC, BRAF MUT, BRAF WT, and DNA SD** contain sodium azide. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. While disposing of sodium azide containing solutions down laboratory sinks, flush the drains with a large volume of cold water to prevent azide buildup.
- P. Xylene is a hazardous chemical and should be used in a chemical hood. Discard into chemical waste in accordance with local, state, and federal regulations.
- Q. Wear eye protection, laboratory coats and disposable gloves when handling any reagents. Avoid contact of these materials with the skin, eyes or mucous membranes. If contact does occur, immediately wash with large amounts of water. Burns can occur if left untreated. If spills occur, dilute with water before wiping dry.
- R. All disposable items are single use. Do not reuse.
- S. Do not use disposable items beyond their expiration date.
- T. Do not use sodium hypochlorite solution (bleach) for cleaning the **cobas z 480** analyzer. Clean the **cobas z 480** analyzer according to procedures described in the **cobas**<sup>®</sup> 4800 System Operator's Manual.

- U. For additional warnings, precautions and procedures to reduce the risk of contamination for the **cobas z** 480 analyzer, consult the **cobas®** 4800 System Operator's Manual.
- V. The use of sterile disposable pipets and DNase-free pipet tips is recommended.

## STORAGE AND HANDLING REQUIREMENTS

- A. Do not freeze reagents.
- B. Store **DNA TLB**, **DNA PBB**, **WB I**, **WB II**, **DNA EB**, **FT** and **CT** at 15–30°C. Once opened, these reagents are stable for up to 8 uses over 90 days or until the expiration date, whichever comes first.
- C. Store **PK** at 15–30°C. After addition of sterile, nuclease-free water to **PK**, store unused reconstituted **PK** in 450 µL aliquots at –20°C. Once reconstituted, **PK** must be used within 90 days or until the expiration date, whichever comes first.
- D. After addition of absolute ethanol, store **WB I** and **WB II** at 15–30°C. These Working Solutions are stable for up to 8 uses over 90 days or until the expiration date, whichever comes first.
- E. Store **RXNMIX**, **MGAC**, **BRAF OM**, **BRAF MUT**, **BRAF WT**, and **DNA SD** at 2–8°C. Once opened, these reagents are stable for up to 4 uses over 60 days or until the expiration date, whichever comes first.
- F. **BRAF OM** and working Master Mix (prepared by the addition of **BRAF OM** and **MGAC** to **RXNMIX**) should be protected from prolonged exposure to light.
- G. Working Master Mix (prepared by the addition of **BRAF OM** and **MGAC** to **RXNMIX**) must be stored at 2–8°C in the dark. The prepared specimens and controls must be added within 1 hour of preparation of the working Master Mix (MMX).
- H. Processed specimens (extracted DNA) are stable for up to 24 hours at 15°C to 30°C or up to 14 days at 2°C to 8°C or up to 60 days at –15°C to –25°C or after undergoing 3 freeze thaws when stored at –15°C to –25°C. Extracted DNA should be amplified within the recommended storage periods or before the expiration date of the **cobas®** DNA Sample Preparation Kit used to extract the DNA, whichever comes first.
- I. Amplification must be started within 1 hour from the time that the processed specimens and controls are added to the working Master Mix (prepared by the addition of **BRAF OM** and **MGAC** to **RXNMIX**).

## MATERIALS PROVIDED

- A. **cobas®** DNA Sample Preparation Kit  
(P/N: 05985536190)

**DNA SP**

**24 Tests**

### **DNA TLB**

(DNA Tissue Lysis Buffer)

### **PK**

(Proteinase K)

### **DNA PBB**

(DNA Paraffin Binding Buffer)

### **WB I**

(DNA Wash Buffer I)

### **WB II**

(DNA Wash Buffer II)

### **DNA EB**

(DNA Elution Buffer)

### **FT**

(Filter tubes with caps)

### **CT**

(Collection Tubes)

B. **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test  
(P/N: 05985579190)

**BRAF**

**24 Tests**

**RXNMIX**

(Reaction Mix) (Cap with Natural Button)

**MGAC**

(Magnesium acetate) (Cap with Yellow Button)

**BRAF OM**

(BRAF Oligo Mix) (Black Cap with White Button)

**BRAF MUT**

(BRAF Mutant Control) (Cap with Red Button)

**BRAF WT**

(BRAF Wild-Type Control) (Cap with Blue Button)

**DNA SD**

(DNA Specimen Diluent) (Cap with Purple Button)

**MATERIALS REQUIRED BUT NOT PROVIDED**

- Xylene (ACS, ≥98.5% xylenes)
- Absolute Ethanol (for Molecular Biology)
- Isopropanol (ACS, ≥995%)
- Sterile Nuclease-free Water (for Molecular Biology)
- Sterile disposable, serological pipettes: 5 and 25 mL
- **cobas**<sup>®</sup> 4800 System Microwell Plate (AD-plate) and Sealing Film (Roche P/N 05232724001)
- Adjustable Pipettors\*: (capacity 10 µL, 20 µL, 200 µL and 1000 µL) with aerosol barrier or positive displacement DNase-free tips
- Pipette Aid (Drummond P/N: 4-000-100 or equivalent)
- Bench top microcentrifuge capable of 20,000 x g
- Two (2) Dry Heat Blocks capable of heating microcentrifuge tubes to 56°C and 90°C\*\*
- 1.5-mL Safe-Lock microcentrifuge tubes, sterile, RNase/DNase free, PCR grade (Eppendorf, Cat# 022363212)
- Spectrophotometer for measuring DNA concentration\*\*
- Vortex mixer\*\*
- Microcentrifuge tube racks
- Disposable gloves, powderless
- Calibrated Thermometers for Dry Heat Block\*\*
- Waterbath\*\* capable of maintaining 37°C
- Single edge blade or similar

\* Pipettors should be maintained according to the manufacturer's instructions and accurate within 3% of stated volume. Aerosol barrier or positive displacement DNase-free tips must be used where specified to prevent specimen degradation and cross-contamination.

\*\*All equipment should be properly maintained according to the manufacturer's instructions.

- **cobas z 480** analyzer
- **cobas<sup>®</sup> 4800 SR2** System Control Unit with OSXP image
- **cobas<sup>®</sup> 4800 SR2** System Software version 2.0 or higher
- BRAF Analysis Package Software version 1.0 or higher
- Barcode Reader (Roche P/N 05339910001)
- Printer HP P2055d (Roche P/N 05704375001)

## SPECIMEN COLLECTION, TRANSPORT AND STORAGE

**NOTE:** *Handle all specimens as if they are capable of transmitting infectious agents.*

### A. Specimen Collection

FFPET specimens have been validated for use with the **cobas<sup>®</sup> BRAF** Test.

### B. Specimen Transport

FFPET specimens can be transported at 15–30°C. Transportation of FFPET specimens must comply with country, federal, state and local regulations for the transport of etiologic agents.<sup>14</sup>

### C. Specimen Storage

Stability of FFPET specimens stored at 15–30°C for up to 9 months after the date of collection has been confirmed. FFPET 5-micron sections mounted on slides may be stored at 15–30°C for up to 60 days.

## INSTRUCTIONS FOR USE

**NOTE:** *All reagents except RXNMIX, MGAC, and BRAF OM must be at ambient temperature prior to use. The RXN MIX, MGAC, and BRAF OM may be taken directly from 2–8°C storage to prepare working Master Mix.*

**NOTE:** *Only melanoma FFPET sections of 5 µm thickness containing at least 50% tumor content are to be used in the cobas<sup>®</sup> 4800 BRAF V600 Mutation Test. Any specimen containing less than 50% tumor content should be macro-dissected prior to deparaffinization.*

**NOTE:** *Refer to the cobas<sup>®</sup> 4800 System Operator's Manual for detailed operating instructions for the cobas z 480 analyzer.*

**NOTE:** *Dry heat blocks, capable of heating microcentrifuge tubes, should be turned on and set at 56°C and 90°C.*

### Run Size

The **cobas<sup>®</sup> BRAF** Test kit is designed to run from a minimum of 3 specimens plus controls up to a maximum of 24 specimens plus controls. Fewer than 3 specimens plus controls can be run at one time, but may result in an insufficient volume of reagents to run a total of 24 specimens plus controls with the kit. The **cobas<sup>®</sup> BRAF** Test contains reagents sufficient for 8 runs of 3 specimens plus controls. One replicate of the **cobas<sup>®</sup> BRAF** Test Mutant Control [**BRAF MU**] and one replicate of the **cobas<sup>®</sup> BRAF** Test Wild-type Control [**BRAF WT**] are required to perform each run (see "Quality Control" section).

### Workflow

**NOTE:** *cobas<sup>®</sup> BRAF Test can be used for up to 24 specimens in a run.*

**NOTE:** *To maximize reagent use, a test run should include a minimum of three (3) patient specimens plus controls.*

The **cobas®** BRAF Test consists of manual sample preparation using the **cobas® DNA Sample Preparation Kit** followed by amplification/detection on the **cobas z 480** analyzer using the **cobas®** BRAF Test kit. Run size can be from one specimen plus controls to 24 specimens plus controls.

#### Reagent Preparation

1. Reconstitute Proteinase K (**PK**) by adding 4.5 mL of sterile (PCR grade) water to the vial using a sterile, disposable 5-mL serological pipette. Mix by inverting the vial 5 to 10 times. Dispense 450-µL aliquots of reconstituted **PK** into 1.5-mL Safe-Lock microcentrifuge tubes and store at -20°C. If the Proteinase K has already been reconstituted and frozen, thaw a sufficient number of aliquots to process the number of specimens to be run prior to deparaffinization (70 µL of reconstituted **PK** is required for each specimen).
2. All solutions stored at 15-30°C should be clear. If precipitate is present in any reagent, warm the solution in a 37°C water bath until the precipitate dissolves. Do not use until all precipitate has been dissolved.
3. Prepare working DNA Wash Buffer I (**WB I**) by adding 15 mL of absolute ethanol to the bottle of **WB I**. Mix by inverting the bottle 5 to 10 times. Note on the bottle that ethanol has been added and the date. Store working **WB I** at 15°C to 30°C.
4. Prepare working DNA Wash Buffer II (**WB II**) by adding 50 mL of absolute ethanol to the bottle of **WB II**. Mix by inverting the bottle 5 to 10 times. Note on the bottle that ethanol has been added and the date. Store working **WB II** at 15°C to 30°C.

#### Deparaffinization of FFPET Sections Mounted on Slides

**Note:** ***Xylene is a hazardous chemical. All steps for deparaffinization should be performed under a chemical hood. See Warnings and Precautions***

- A. Add a slide with mounted 5-µm FFPET section to a container with sufficient xylene to cover tissue, and soak for 5 minutes.
- B. Transfer slide to container with sufficient absolute ethanol to cover tissue and soak for 5 minutes.
- C. Remove slide and allow section to air dry completely (5 to 10 minutes).
- D. Perform macrodissection if specimen contains <50% tumor content.
- E. Label one 1.5-mL Safe-Lock microcentrifuge tube for each specimen with the specimen identification information.
- F. Add 180 µL **DNA TLB** into the labeled 1.5-mL Safe-Lock microcentrifuge tube.
- G. Add 70 µL of reconstituted **PK** to the 1.5-mL Safe-Lock microcentrifuge tube containing **DNA TLB**.
- H. Scrape the tissue off the slide and immerse into the **DNA TLB** and **PK** mixture.
- I. Continue to Step A of the **DNA Isolation** procedure.

#### Deparaffinization of FFPET Sections not Mounted on Slides

**Note:** ***Xylene is a hazardous chemical. All steps for deparaffinization should be performed under a chemical hood. See Warnings and Precautions***

- A. Macrodissection for specimens that contains <50% tumor content is required. Place one 5-µm FFPET section into a 1.5-mL Safe-Lock microcentrifuge tube labeled with the specimen identification information for each specimen.
- B. Add 500 µL Xylene to a Safe-Lock microcentrifuge tube containing the FFPET section.
- C. Mix well by vortexing for 10 seconds.
- D. Let the tube stand for 5 minutes at 15°C-30°C.
- E. Add 500 µL absolute ethanol and mix by vortexing for 10 seconds.

- F. Let the tube stand for 5 minutes at 15°C–30°C.
- G. Centrifuge at 16,000 x g to 20,000 x g for 2 minutes and remove supernatant without disturbing the pellet. Discard the supernatant into chemical waste.
- H. Add 1 mL absolute ethanol and vortex for 10 seconds.
- I. Centrifuge at 16,000 x g to 20,000 x g for 2 minutes and remove the supernatant without disturbing the pellet. Discard the supernatant into chemical waste.

**NOTE:** *If the pellet is floating in the remaining supernatant, spin again for 1 minute at 16,000 x g to 20,000 x g. Remove any remaining supernatant.*

- J. Dry the tissue pellet for 10 minutes at 56°C in a heating block with tubes open.

**NOTE:** *Make sure the ethanol is completely evaporated and pellet is dry before proceeding to the next step.*

**NOTE:** *If needed, dry pellets can be stored up to 24 hours at 2–8°C.*

- K. Resuspend tissue pellet in 180 µL of DNA Tissue Lysis Buffer (**DNA TLB**).
- L. Add 70 µL of reconstituted **PK**.
- M. Continue to Step A of the **DNA Isolation** procedure.

#### DNA Isolation

- A. Vortex tube with specimen/**DNA TLB/PK** mixture for 30 seconds.

**NOTE:** *The tissue must be fully immersed in the DNA TLB/PK mixture.*

- B. Place tube in 56°C dry heat block and incubate for 60 minutes.
- C. Vortex the tube for 10 seconds.

**NOTE:** *The tissue must be fully immersed in the DNA TLB/PK mixture.*

- D. Place tube in 90°C dry heat block and incubate for 60 minutes.

**NOTE:** *During the incubation, prepare the required number of filter tubes (FT) with hinged caps by placing onto collection tubes (CT) and label each FT/CT unit with proper identification on the cap of each FT.*

**NOTE:** *Each specimen will need 1 FT, 3 CT and one elution tube (1.5 mL microcentrifuge tube).*

**NOTE:** *During the incubation, label the required number of elution tubes (1.5-mL microcentrifuge tubes) with proper specimen identification information.*

- E. Allow the tube to cool to 15°C–30°C. After cooling, pulse centrifuge to collect any excess liquid from the cap.
- F. Add 200 µL **DNA PBB** and mix by pipetting up and down 3 times.
- G. Incubate tube at 15°C–30°C for 10 minutes.
- H. Add 100 µL isopropanol and mix lysate by pipetting up and down 3 times.
- I. Transfer all of the lysate into the appropriately labeled **FT/CT** unit.
- J. Centrifuge **FT/CT** units at 8,000 x g for 1 minute.
- K. Place **FT** onto a new **CT**. Discard the flow-through from the old **CT** into chemical waste and properly dispose of the old **CT**.
- L. Add 500 µL working **WB I** to the **FT**.

**NOTE:** *Preparation of working WB I is described in the Reagent Preparation section.*

- M. Centrifuge **FT/CT** units at 8,000 x g for 1 minute.
- N. Discard the flow-through in each **CT** into chemical waste. Place **FT** back into the same **CT**.
- O. Add 500 µL working **WB II** to the **FT**.

**NOTE:** *Preparation of working WB II is described in the Reagent Preparation section.*

- P. Centrifuge **FT/CT** units at 8,000 x g for 1 minute.
- Q. Place **FT** onto a new **CT**. Discard the flow-through from the old **CT** into chemical waste and properly dispose of the old **CT**.
- R. Centrifuge **FT/CT** unit at 16,000 to 20,000 x g for 1 minute to dry the filter membrane.
- S. Place the **FT** tube into an elution tube (1.5-mL microcentrifuge tube) pre-labeled with specimen identification information. Discard the flow-through from the old **CT** into chemical waste and properly dispose of the old **CT**.
- T. Add 100 µL **DNA EB** to the center of the **FT** membrane without touching the **FT** membrane.
- U. Incubate **FT** with elution tube at 15°C-30°C for 5 minutes.
- V. Centrifuge **FT** with elution tube at 8,000 x g for 1 minute to collect eluate into the elution tube (pre-labeled 1.5-mL microcentrifuge tube). Properly dispose of the **FT**. The eluate is the **DNA stock**.
- W. Close caps on elution tubes. Continue with Step A in the DNA Quantitation section.

**NOTE:** *DNA quantitation should be performed immediately after the DNA Isolation procedure and prior to storage.*

#### DNA Quantitation

- A. Mix each DNA stock by vortexing for 5 seconds before quantitation.
- B. Quantify DNA using a spectrophotometer according to the manufacturer's protocol. Use **DNA EB** as the blank for the instrument. An average of 2 consistent readings is necessary. The two measurements should be within ±10% of each other when the DNA concentration readings are ≥ 20.0 ng/µL. For DNA concentration readings <20.0 ng/µL, the two measurements should be within ±2.0 ng/µL.
- C. DNA stock concentration must be ≥ 5 ng/µL to perform the **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test.

**NOTE:** *Each DNA stock must have a minimum concentration of 5 ng/µL to perform the cobas<sup>®</sup> BRAF Test. If the concentration of a DNA stock is < 5 ng/µL, the DNA Isolation procedure should be repeated for that specimen using two 5 µm FFPET sections. Continue with Step A of "Deparaffinization of FFPET Sections Mounted on Slides" or Step A of "Deparaffinization of FFPET Sections Not Mounted on Slides" combining the tissue from both slides/sections into one tube. Continue with the DNA Isolation procedure. If the DNA stock is still < 5 ng/µL, another FFPET specimen may need to be requested from the referring clinical site.*

**NOTE:** *Processed specimens (extracted DNA) are stable for up to 24 hours at 15°C to 30°C or up to 14 days at 2°C to 8°C or up to 60 days at -15°C to -25°C or after undergoing 3 freeze thaws when stored at -15°C to -25°C. Extracted DNA should be amplified within the recommended storage periods or before the expiration date of the cobas<sup>®</sup> DNA Sample Preparation Kit used to extract the DNA, whichever comes first.*

## AMPLIFICATION AND DETECTION

**NOTE:** *To avoid contamination of the working Master Mix with DNA specimens, Amplification and Detection should be performed in an area separated from DNA Isolation. The amplification and detection work area should be thoroughly cleaned before working Master Mix preparation. For proper cleaning, all surfaces including racks and pipettors should be thoroughly wiped with 0.5% sodium hypochlorite solution followed by wiping with a 70% ethanol solution. Commercial liquid household bleach typically contains sodium hypochlorite at a concentration of 5.25%. A 1:10 dilution of household bleach will produce a 0.5% sodium hypochlorite solution.*

### Instrument Set-Up

Refer to the **cobas**<sup>®</sup> 4800 Instrument Operator's Manual for detailed instruction for the **cobas z** 480 set-up.

### Test Order Set-Up

Refer to the **cobas**<sup>®</sup> 4800 System Operator's Manual for **cobas**<sup>®</sup> BRAF Test (**cobas**<sup>®</sup> BRAF Operator's Manual) for detailed instructions on the BRAF workflow steps.

### Dilution Calculation of Specimen DNA Stock

Only one amplification/detection is run per specimen, using 25 µL of a 5 ng/µL dilution of DNA stock (125 ng in total). The instructions below describe how to prepare a minimum of 35 µL of diluted DNA stock at 5 ng/µL, dependent on the initial DNA stock concentration. This will ensure each specimen uses a minimum of 5 µL of DNA stock to prevent variation that may occur when pipetting smaller volumes of sample:

#### Dilution Calculation of Specimen DNA Stock at Concentrations from 5 ng/µL to 35 ng/µL

**NOTE:** *DNA stocks from specimens should be diluted immediately prior to amplification and detection.*

**NOTE:** *Only one amplification/detection is run per specimen, using 25 µL of a 5 ng/µL dilution of DNA stock (125 ng in total).*

- A. For each specimen, determine the amount of DNA stock required using the following formula:

Volume of DNA stock required = (35 µL x 5 ng/µL) / DNA stock concentration in ng/µL

- B. For each specimen, determine the amount of DNA Specimen Diluent (**DNA SD**) required using the following formula:

Volume of DNA SD required in µL = (35 µL - Volume of DNA stock required in µL)

Example:

DNA stock concentration = 21 ng/µL

- A. Volume of DNA stock required = (35 µL x 5 ng/µL) / 21 ng/µL = 8.3 µL

- B. Volume of DNA SD required in µL = (35 µL - 8.3 µL) = 26.7 µL

#### Dilution Calculation of Specimen DNA Stock at Concentrations >35 ng/µL

**NOTE:** *DNA stocks from specimens should be diluted immediately prior to amplification and detection.*

**NOTE:** *Only one amplification/detection is run per specimen, using 25 µL of a 5 ng/µL dilution of DNA stock (125 ng in total).*

- A. At DNA stock concentrations >35 ng/µL, use the following formula to calculate the amount of DNA Specimen Diluent (**DNA SD**) required to prepare 35 µL of diluted DNA stock. This is to ensure each specimen uses a minimum of 5 µL of DNA stock,

Vol. of DNA SD required in µL = ((5 µL DNA stock x DNA stock conc. in ng/µL) / (5ng/µL)) - 5 µL

- B Use the calculated volume of **DNA SD** to dilute 5 µL of DNA stock

Example:

DNA stock concentration = 42 ng/µL

- A. Vol. of DNA SD required in µL =  $((5 \mu\text{L} \times 42 \text{ ng}/\mu\text{L}) / (5 \text{ ng}/\mu\text{L})) - 5 \mu\text{L} = 37 \mu\text{L}$
- B. Use the calculated volume of **DNA SD** to dilute 5 µL of DNA stock.

#### Specimen Dilution

- A. Prepare the appropriate number of 1.5 mL Safe-Lock microcentrifuge tubes for specimen DNA stock dilutions by labeling them with the proper specimen identification in the specimen addition area.
- B. Using a pipettor with an aerosol-resistant pipette tip, pipette the calculated volume of DNA Specimen Diluent (**DNA SD**) into each labeled specimen tube.
- C. Vortex each specimen DNA stock for 10 seconds.
- D. Using a pipettor with an aerosol-resistant pipette tip, gently pipette the calculated volume of each specimen DNA stock into the properly labeled tube containing **DNA SD**. Use a new pipette tip for each specimen.
- E. Cap and mix each diluted specimen DNA stock by vortexing 10 seconds.
- F. Change gloves.

#### Preparation of Working Master Mix (MMX)

**NOTE:** *The BRAF Oligo Mix and working MMX are light-sensitive. All open mixtures of BRAF OM and working MMX should be protected from prolonged exposure to light.*

- A. Calculate the volume of **RXNMIX** required using the following formula:  
Volume of **RXNMIX** required = (Number of Specimens + 2 Controls + 1) x 10 µL
- B. Calculate the volume of **BRAF OM** required using the following formula:  
Volume of **BRAF OM** required = (Number of Specimens + 2 Controls + 1) x 8 µL
- C. Calculate the volume of **MGAC** required using the following formula:  
Volume of **MGAC** required = (Number of Specimens + 2 Controls + 1) x 7 µL

Table 1 may be used to determine volumes of each reagent needed for the preparation of working MMX based on the number of specimens included in the run.

**Table 1**

|                      |              | Volumes of Reagents Needed for Working MMX<br># of Specimens* |            |            |            |            |            |            |            |            |            |
|----------------------|--------------|---------------------------------------------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
|                      |              | 1                                                             | 2          | 3          | 4          | 5          | 6          | 7          | 8          | 9          | 10         |
| <b>RXN MIX</b>       | <b>10 µL</b> | 40                                                            | 50         | 60         | 70         | 80         | 90         | 100        | 110        | 120        | 130        |
| <b>BRAF OM</b>       | <b>8 µL</b>  | 32                                                            | 40         | 48         | 56         | 64         | 72         | 80         | 88         | 96         | 104        |
| <b>MGAC</b>          | <b>7 µL</b>  | 28                                                            | 35         | 42         | 49         | 56         | 63         | 70         | 77         | 84         | 91         |
| <b>Total Vol. µL</b> |              | <b>100</b>                                                    | <b>125</b> | <b>150</b> | <b>175</b> | <b>200</b> | <b>225</b> | <b>250</b> | <b>275</b> | <b>300</b> | <b>325</b> |

\* # of Specimens + 2 Controls + 1

- D. Remove appropriate number of **RXNMIX**, **BRAF OM** and **MGAC** vials from 2°-8°C storage. Vortex each reagent for 5 seconds to collect liquid at the bottom of the tube before use. Label a sterile microcentrifuge tube as MMX for the working Master Mix (MMX).
- E. Add the calculated volume of **RXNMIX** to the labeled MMX tube.
- F. Add the calculated volume of **BRAF OM** to the labeled MMX tube.
- G. Add the calculated volume of **MGAC** to the labeled MMX tube.
- H. Vortex tube for 5 seconds to assure adequate mixing.

**NOTE:** Use only **cobas® 4800 System Microwell Plate (AD-plate)** and **Sealing Film (Roche P/N 05232724001)**

- I. Carefully add 25 µL of working MMX to each reaction well of the microwell plate (AD-plate) that is needed for the run. Do not allow the pipette tip to touch the plate outside that well.

#### Addition of Controls and Specimens

- A. Add 25 µL of **BRAF MUT** Control to well **A01** of the microwell plate (AD-plate) and mix well using pipettor to aspirate and dispense within the well a minimum of two times.
- B. Using a new pipette tip, add 25 µL of **BRAF WT** Control to well **B01** of the microwell plate (AD-plate) and mix well using pipettor to aspirate and dispense within the well a minimum of two times.

**NOTE:** Each run must contain both a **BRAF MUT** Control in position **A01** and a **BRAF WT** Control in position **B01** or the run will be invalidated by the **cobas z 480 analyzer**.

**NOTE:** Change gloves as needed to protect against specimen-to-specimen contamination and external PCR reaction tube contamination.

- C. Using a pipettor with an aerosol-resistant tip, add 25 µL of diluted specimen DNA to the appropriate well containing working MMX, starting from position **C01** on the microwell plate (AD-plate) following the template in Figure 1 below. Mix the reaction by using the pipettor to aspirate and dispense within the well a minimum of two times. Ensure that all liquid is collected at the bottom of the well.

**NOTE:** Specimen DNA and Controls should be added to the microwell plate (AD-plate) within 1 hour after the preparation of the working Master Mix (MMX)

**Figure 1**

| Sample Plate Layout |             |              |              |              |   |   |   |   |   |    |    |
|---------------------|-------------|--------------|--------------|--------------|---|---|---|---|---|----|----|
|                     | 1           | 2            | 3            | 4            | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| A                   | BRAF<br>MUT | Sample<br>7  | Sample<br>15 | Sample<br>23 |   |   |   |   |   |    |    |
| B                   | BRAF<br>WT  | Sample<br>8  | Sample<br>16 | Sample<br>24 |   |   |   |   |   |    |    |
| C                   | Sample<br>1 | Sample<br>9  | Sample<br>17 |              |   |   |   |   |   |    |    |
| D                   | Sample<br>2 | Sample<br>10 | Sample<br>18 |              |   |   |   |   |   |    |    |
| E                   | Sample<br>3 | Sample<br>11 | Sample<br>19 |              |   |   |   |   |   |    |    |
| F                   | Sample<br>4 | Sample<br>12 | Sample<br>20 |              |   |   |   |   |   |    |    |
| G                   | Sample<br>5 | Sample<br>13 | Sample<br>21 |              |   |   |   |   |   |    |    |
| H                   | Sample<br>6 | Sample<br>14 | Sample<br>22 |              |   |   |   |   |   |    |    |

- D. Continue until all test specimens have been added to the microwell plate (AD-plate).
- E. Cover the microwell plate (AD-plate) with the sealing film (supplied with the plates). Use the sealing film applicator to ensure that the sealing film adheres firmly to the microwell plate (AD-plate).
- F. Confirm that all liquid is collected at the bottom of each well before starting Amplification and Detection.

**NOTE:** *Amplification and detection should be started within 1 hour after the addition of Specimen DNA and Controls to the working MMX.*

Starting PCR

Refer to the **cobas**<sup>®</sup> 4800 System, Operator's Manual for **cobas**<sup>®</sup> 4800 BRAF V600 Mutation Test for detailed instructions for the BRAF workflow steps.

## INTERPRETATION OF RESULTS

**NOTE:** *All run and specimen validation is performed by the cobas<sup>®</sup> 4800 BRAF AP Software.*

**NOTE:** *A valid run may include both valid and invalid specimen results.*

For a valid run, specimen results are interpreted as shown in Table 2.

**Table 2**  
**Interpretation of Specimen Results**

| <b>cobas<sup>®</sup> BRAF Test Result</b>            | <b>Interpretation</b>                                                                                                                                                              |
|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mutation Detected                                    | V600 Mutation Detected in the BRAF codon 600 site in exon 15                                                                                                                       |
| Mutation Not Detected<br>or<br>No Mutation Detected* | V600 Mutation Not Detected in the BRAF codon 600 site in exon 15                                                                                                                   |
| Invalid                                              | Result is invalid.<br>Repeat the testing of specimens with invalid results following the instructions outlined in the "Retesting of Specimens with Invalid Results" section below. |
| Failed                                               | Failed run due to hardware or software failure                                                                                                                                     |

\* A Mutation Not Detected or No Mutation Detected result does not preclude the presence of a mutation in the BRAF codon 600 site since results depend on percent mutant sequences, adequate specimen integrity, absence of inhibitors, and sufficient DNA to be detected.

All of the patients in the phase III study NO25026 (BRIM3)<sup>7</sup> sponsored by Hoffmann-LaRoche were selected using the **cobas**<sup>®</sup> BRAF Test. Enrollment in the study was limited to patients whose melanoma tissue test result was "Mutation Detected" by the test. Therefore it is not known whether patients whose result is "Mutation Not Detected" or "No Mutation Detected" by the **cobas**<sup>®</sup> BRAF Test will benefit from ZELBORAF<sup>®</sup> treatment. The **cobas**<sup>®</sup> BRAF Test result was "Mutation Detected" for 97% of specimens that were Sanger positive for V600E and for approximately 66% of specimens that were Sanger positive for V600K, based on comparison of results from testing clinical specimens (see Table 11).

### Retesting of Specimens with Invalid Results

- A. Repeat dilution of the invalid specimen DNA stock starting from "**Dilution Calculation of Specimen DNA Stock**" and "**Specimen Dilution**" procedures in the "**AMPLIFICATION and DETECTION**" section.

**Note:** *If there is not enough specimen DNA stock remaining to perform a new dilution of the DNA stock, obtain a new 5-µm section of tissue and start with the "Deparaffinization of FFPE Sections Mounted on Slides" or "Deparaffinization of FFPE Sections not Mounted on Slides" procedure, then proceed with Step B below.*

- B. After performing the DNA stock dilution to 5 ng/µL described in "**Specimen Dilution**", perform an additional 1:2 dilution by taking 20 µL of the diluted DNA stock and adding 20 µL of DNA Specimen Diluent (DNA SD).
- C. Continue with "**Preparation of Working Master Mix (MMx)**" and the remainder of the amplification and detection procedure.

**Note:** *If the specimen remains invalid after retesting at a 1:2 dilution, repeat the entire test procedure for that specimen, starting with Deparaffinization and DNA Isolation using a new 5-µm FFPE section. The standard 25 µL of DNA at 5 ng/µL (without further dilution) should be used for amplification and detection.*

## QUALITY CONTROL

The **cobas**<sup>®</sup> BRAF Test Mutant (**BRAF MUT**) Control and Wild-type (**BRAF WT**) Control are included in each run. A run is valid if both the **BRAF MUT** Control well (**A01**) and the **BRAF WT** Control well (**B01**) have a valid control status. In order for a mutant control to be called valid, the Ct value needs to be between 23.5 to 30.5 in the mutant channel, and between 23.5 to 29.0 in the wild-type channel. In order for a wild-type control to be called valid, the Ct value needs to be >43 in the mutant channel and between 31.5 to 38.5 in the wild-type channel. If either the **BRAF MUT** Control or **BRAF WT** Control is invalid, the run must be repeated. Prepare a fresh dilution of the previously isolated specimen DNA stock to set up a new microwell plate (AD-plate) with controls for amplification and detection.

### BRAF Mutant Control

The **BRAF MUT** Control result must be 'Valid'. If the **BRAF MUT** Control results are consistently invalid, contact your local Roche office for technical assistance.

### BRAF Wild-Type Control

The **BRAF WT** Control result must be 'Valid'. If the **BRAF WT** Control results are consistently invalid, contact your local Roche office for technical assistance.

## PROCEDURAL PRECAUTIONS

As with any test procedure, good laboratory technique is essential to the proper performance of this assay. Due to the high analytical sensitivity of PCR-based tests, care should be taken to keep reagents and amplification mixtures free of contamination.

## PROCEDURAL LIMITATIONS

1. Test only the indicated specimen types. The **cobas**<sup>®</sup> BRAF Test has been validated for use only with melanoma FFPE specimens.
2. The **cobas**<sup>®</sup> BRAF Test has been validated using only the **cobas**<sup>®</sup> DNA Sample Preparation Kit (Roche P/N: 05985536190) to extract genomic DNA.
3. Detection of a mutation is dependent on the number of mutant sequence copies present in the specimen and may be affected by specimen integrity, amount of isolated DNA, and the presence of interfering substances.
4. Reliable results are dependent on adequate specimen fixation, transport, storage and processing. Follow the procedures in this Package Insert and in the **cobas**<sup>®</sup> 4800 System Operator's Manual.
5. The addition of AmpErase enzyme into the **cobas**<sup>®</sup> 4800 BRAF V600 Master Mix enables selective amplification of target DNA; however, good laboratory practices and careful adherence to the procedures specified in this Package Insert are necessary to avoid contamination of reagents.
6. Use of this product must be limited to personnel trained in the techniques of PCR and the use of the **cobas**<sup>®</sup> 4800 System.
7. Only the **cobas**<sup>®</sup> 4800 System has been validated for use with this product. No other PCR system has been validated with this product.
8. Though rare, mutations and variants within the regions of the BRAF gene covered by the primers or probes used in the **cobas**<sup>®</sup> BRAF Test may result in failure to amplify the BRAF V600 allele or detect the presence of mutation in codon 600.
9. The presence of PCR inhibitors may cause false negative or invalid results.
10. Melanin is a known inhibitor of PCR reactions. The DNA sample preparation kit removes melanin from the specimen during extraction; however, melanin in a specimen may still cause invalid results. If

melanin inhibition is suspected, repeat testing using a 1:2 dilution is suggested as described in **“Retesting of Specimens with Invalid Results.”**

11. The **cobas**<sup>®</sup> BRAF Test shows limited cross-reactivity with non-V600E mutant specimens (V600K, V600D)). The assay may not detect V600E2 mutations. Refer to the Non-clinical Performance Evaluation section for more details.
12. FFPET specimens containing degraded DNA may affect the ability of the test to detect the V600E mutation.
13. The **cobas**<sup>®</sup> BRAF Test is a qualitative test. The test is not for quantitative measurements of mutation.

## NON-CLINICAL PERFORMANCE EVALUATION

For the nonclinical studies described below, % tumor was assessed by pathology review and melanin content was assessed by pathology review. Bi-directional Sanger sequencing was used to select the specimens for testing. The % mutation was determined using a parallel sequencing method.

### Analytical Sensitivity – Limit of Blank (LoB)

To assess performance of the **cobas**<sup>®</sup> BRAF Test in the absence of template and to ensure that a blank sample, or a sample with an excess of 100% wildtype DNA, does not generate an analytical signal that might indicate a low concentration of mutation, samples with no template and 100% BRAF wild-type DNA were evaluated. No detectable Ct results were identified in the mutant channel in the presence of 100% BRAF wild-type DNA or in either channel following a no template sample. Additionally, no detectable Ct was identified in the wild-type channel when testing a 100% BRAF V600E sample.

### Analytical Sensitivity - Limit of Detection (LoD)

The minimum amount of input DNA that produces correct results 95% of the time was assessed using dilution panels prepared from three types of specimens:

- Specimen blends prepared by mixing DNA stocks obtained from BRAF V600E mutant FFPET specimens and BRAF wild-type FFPET specimens to achieve specific mutation levels.
- Individual FFPET DNA stocks prepared from three BRAF V600E mutant FFPET specimens.
- Cell line blend prepared by mixing DNA stocks obtained from a BRAF V600E mutant cell line and a BRAF wild-type cell line.

### Analytical Sensitivity Using Specimen Blends

BRAF V600E mutant FFPET specimen DNA stocks were blended with BRAF wild-type FFPET specimen DNA stocks to achieve one specimen at ~10%, three specimens at ~5%, and one specimen at ~3% mutation level. One BRAF wild-type specimen was also tested. Each of the five specimen blends with V600E mutation (but not the wild-type specimen) was then diluted to produce panel members at a range of DNA concentrations (125 ng to 0.3 ng in a 25 µL volume).

Eight (8) replicates of each panel member were run using each of 3 **cobas**<sup>®</sup> BRAF Test kit lots (n=24/panel member). This study demonstrated that in FFPET specimen blends, the **cobas**<sup>®</sup> BRAF V600 Test can detect the BRAF V600E mutation at ≥5% mutation level using the standard input of 125 ng/25 µL. The ~10% blend correctly called all replicates at a 31 ng/25 µL dilution. The 3% FFPET blend at 125 ng/25 µL was not detected.

### Analytical Sensitivity Using FFPET Specimens

To confirm the 5% claim in patient specimens, forty-eight individual 5 µm sections from each of 3 BRAF V600E mutant FFPET specimens containing 5%, 6%, and 12%, mutation levels were individually processed using 3 lots of **cobas**<sup>®</sup> DNA Sample Preparation Kit to isolate the DNA. To assess the impact of melanin on the assay, one specimen (6% mutation) had a high melanin concentration. Serial dilutions of the DNA from each section were prepared to produce a set of 6 panel members at a range of DNA concentrations (125 ng to 0.5 ng in a 25 µL volume).

Sixteen (16) replicates of each panel member were run using each of 3 **cobas**<sup>®</sup> BRAF Test kit lots (n=48/panel member).

The study demonstrated that the **cobas**<sup>®</sup> BRAF Test can detect the BRAF V600E mutation in actual clinical FFPET specimens at  $\geq 5\%$  mutation level using the standard input of 125 ng/25  $\mu\text{L}$ .

#### Analytical Sensitivity Using Cell Line Blend

DNA stocks from two melanoma cell lines [SK-MEL 28 (BRAF V600E mutant) and SK-MEL 2 (BRAF wild-type)] were blended to achieve a sample at 5% mutation. Three separate dilution panels containing from 125 ng/25  $\mu\text{L}$  to 0.5 ng/25  $\mu\text{L}$  DNA were prepared. Twenty (20) replicates of each panel member were tested, using each of 3 **cobas**<sup>®</sup> BRAF Test kit lots (60 replicates total). Sensitivity was determined by the lowest amount of DNA that gave a BRAF V600E "Mutation Detected" rate of at least 95%. The results of the study are shown in Table 3 below.

**Table 3**  
**Sensitivity of the cobas<sup>®</sup> BRAF Test using Cell Line Blend**

| Cell Line Blend | Mean Percent Mutation | Amount of DNA in the Panel Member | "Mutation Detected" Rate (n=60) |
|-----------------|-----------------------|-----------------------------------|---------------------------------|
| Cell Line Blend | 5%                    | 125.0 ng/25 $\mu\text{L}$         | 97%                             |
|                 |                       | 31.3 ng/25 $\mu\text{L}$          | 100%                            |
|                 |                       | 15.6ng/25 $\mu\text{L}$           | 95%                             |
|                 |                       | 7.8 ng/25 $\mu\text{L}$           | 98%                             |
|                 |                       | 3.9 ng/25 $\mu\text{L}$           | 95%                             |
|                 |                       | 2.0 ng/25 $\mu\text{L}$           | 82%                             |
|                 |                       | 1.0 ng/25 $\mu\text{L}$           | 78%                             |
|                 |                       | 0.5 ng/25 $\mu\text{L}$           | 77%                             |

The **cobas**<sup>®</sup> BRAF Test gave a 95% "Mutation Detected" rate at 3.9 ng/25 $\mu\text{L}$ , which represents a 1:32 dilution of the recommended DNA input of 125 ng/25  $\mu\text{L}$ .

#### Genomic Input Range

The recommended DNA input for the **cobas**<sup>®</sup> BRAF Test is 125 ng. Various genomic DNA input amounts may result from DNA quantitation errors and/or variation in the amount of degraded DNA. To evaluate the effects of various genomic DNA input amounts, genomic DNA was extracted from 11 melanoma FFPET specimens, selected for their mutation status and level of pigmentation, and serially diluted with sample input representing 250 ng, 125 ng, 62.5 ng, and 31.3 ng/ 25  $\mu\text{L}$ . All 4 DNA levels were evaluated using 2 lots. The expected results were obtained for all genomic DNA input levels.

#### Minimal Tumor Content

Thirty-three (33) BRAF V600E mutant specimens were tested to determine the minimum tumor proportion required for detecting the BRAF V600E mutation in specimens with tumor content ranging from 5% to 50%, without macro-dissection. One (1) section from each specimen was tested using the **cobas**<sup>®</sup> BRAF Test.

The **cobas**<sup>®</sup> BRAF Test correctly detected all BRAF V600E mutant specimens that had a minimum % mutant DNA above 5% and when the minimum tumor content was at least 15% as shown in Table 4. Specimens whose tumor content was less than 15% tumor content and less than 5% mutation were reported as mutation-not-detected. An additional 24 wild-type specimens with tumor content ranging from 5 to 45% were evaluated at the recommended DNA input concentration of 125 ng in 25  $\mu\text{L}$  as well. All wild-type specimens were correctly called. Macrodissection for specimens that contain <50% tumor content is required.

**Table 4**  
**Results of Testing 33 BRAF V600 FFPET Specimens with Various Percent Tumor Content**

| V600E Specimen Number | Tumor Content* | Test Result           |
|-----------------------|----------------|-----------------------|
| 1                     | 5% / 5%        | Mutation Not Detected |
| 2                     | 5% / 5%        | Mutation Not Detected |
| 3                     | 5% / 5%        | Mutation Not Detected |
| 4                     | 10% / 10%      | Mutation Not Detected |
| 5                     | 10% / 10%      | Mutation Detected     |
| 6                     | 15% / 10%      | Mutation Detected     |
| 7                     | 15% / 15%      | Mutation Detected     |
| 8                     | 15% / 15%      | Mutation Detected     |
| 9                     | 15% / 15%      | Mutation Detected     |
| 10                    | 15% / 15%      | Mutation Detected     |
| 11                    | 15% / 15%      | Mutation Detected     |
| 12                    | 15% / 20%      | Mutation Detected     |
| 13                    | 20% / 20%      | Mutation Detected     |
| 14                    | 20% / 20%      | Mutation Detected     |
| 15                    | 25% / 20%      | Mutation Detected     |
| 16                    | 25% / 25%      | Mutation Detected     |
| 17                    | 30% / 25%      | Mutation Detected     |
| 18                    | 30% / 30%      | Mutation Detected     |
| 19                    | 30% / 35%      | Mutation Detected     |
| 20                    | 30% / 35%      | Mutation Detected     |
| 21                    | 35% / 30%      | Mutation Detected     |
| 22                    | 35% / 35%      | Mutation Detected     |
| 23                    | 35% / 35%      | Mutation Detected     |
| 24                    | 35% / 35%      | Mutation Detected     |
| 25                    | 35% / 40%      | Mutation Detected     |
| 26                    | 40% / 35%      | Mutation Detected     |
| 27                    | 40% / 35%      | Mutation Detected     |
| 28                    | 40% / 40%      | Mutation Detected     |
| 29                    | 40% / 40%      | Mutation Detected     |
| 30                    | 40% / 40%      | Mutation Detected     |
| 31                    | 40% / 45%      | Mutation Detected     |
| 32                    | 45% / 45%      | Mutation Detected     |
| 33                    | 50% / 40%      | Mutation Detected     |

*\*Tumor content of the specimen was assessed by examining the first and last of twelve adjacent 5-µm sections of each specimen by a pathologist. The tumor content of both the first and the last section is shown (for example, 95% / 95%).*

## Cross-Reactivity

Cross-reactivity of the **cobas**<sup>®</sup> BRAF Test was evaluated by testing the following specimen types:

- BRAF non-V600E mutant melanoma FFPE specimens at various mutation levels,
- Plasmids of BRAF non-V600E mutations,
- Plasmids of BRAF homologs,
- Skin-related microorganisms.

Cross-reactivity was also evaluated by determining whether the presence of BRAF homolog plasmids or skin-related microorganisms interfered with detection of the BRAF V600E mutation.

### BRAF Non-V600E Melanoma FFPE Specimens

Fourteen (14) melanoma FFPE specimens with BRAF non-V600E mutations (V600D, V600E2, V600R, or V600K) were tested in triplicate with the **cobas**<sup>®</sup> BRAF Test. For eight of the BRAF non-V600E specimens, all three replicates showed cross-reactivity with the **cobas**<sup>®</sup> BRAF Test. These eight specimens were: BRAF V600D mutant (18% mutation), BRAF V600E2 mutant (68.0% mutation), or BRAF V600K mutant (greater than 30% mutation). No cross-reactivity was observed for the BRAF V600R mutant (23% mutation) specimen as shown in Table 5.

**Table 5**  
***cobas*<sup>®</sup> BRAF Test Mutation Detected Rates Observed for BRAF Non-V600E Mutations in FFPE Specimens\***

| Specimen Number | BRAF Mutation Status | Percent Mutation | Tumor Content <sup>a</sup> | Tumor Stage | Mutation Detected Rate (n=3) |
|-----------------|----------------------|------------------|----------------------------|-------------|------------------------------|
| 1               | V600D                | 18%              | 30% / 30%                  | IV          | 100%                         |
| 2               | V600E2               | 16%              | 75% / 75%                  | IV          | 0%                           |
| 3               |                      | 36%              | 75% / 80%                  | III         | 0%                           |
| 4               |                      | 68%              | 75% / 75%                  | IV          | 100%                         |
| 5               | V600R                | 23%              | 15% / 15%                  | IV          | 0%                           |
| 6               | V600K*               | 17%              | 25%/25%                    | III         | 0%                           |
| 7               |                      | 22%              | 35% / 40%                  | IV          | 0%                           |
| 8               |                      | 23%              | 40% / 40%                  | IV          | 0%                           |
| 9               |                      | 31%              | 60% / 60%                  | IV          | 100%                         |
| 10              |                      | 35%              | 75% / 75%                  | IV          | 100%                         |
| 11              |                      | 40%              | 80% / 80%                  | IV          | 100%                         |
| 12              |                      | 36%              | 95% / 95%                  | IIC         | 100%                         |
| 13              |                      | 62%              | 75% / 75%                  | IV          | 100%                         |
| 14              |                      | 69%              | 80% / 80%                  | IV          | 100%                         |

<sup>a</sup>Tumor content of the specimen was assessed by examining the first and last of twelve adjacent 5-µm sections of each specimen by a pathologist. The tumor content of both the first and the last section is shown (for example, 95% / 95%).

\*The **cobas**<sup>®</sup> BRAF Test does not reliably detect V600E2 and non-V600E mutations. Sanger sequencing analysis of 449 BRIM3 clinical trial samples demonstrated that the assay is cross-reactive with 66% of V600K mutation cases (Table 11).

### BRAF Non-V600E Plasmids

Plasmid dilution panels with mutation levels ranging from 5% to 75% in a background of wild-type plasmid, were prepared for the following nine BRAF non-V600E mutations: D594G, G596R, K601E, L597Q, L597S, V600D, V600E2, V600K, and V600R. Three replicates of each member of the dilution panels prepared for each plasmid were tested using the **cobas**<sup>®</sup> BRAF Test. Cross-reactivity was seen in all 3 replicates for BRAF V600D plasmid at ≥ 10 % mutation, BRAF V600K plasmid at ≥ 35 % mutation, and BRAF V600E2 plasmid at ≥ 65 % mutation. No cross-reactivity was observed with plasmids from the six other BRAF mutations tested.

### Plasmids of BRAF Homologs

Samples were prepared for three BRAF homolog plasmids (BRAF Pseudogene, ARAF, and RAF1), BRAF V600E mutant plasmid, and BRAF wild-type plasmid as outlined in Table 6. Three to six replicates of each panel member were tested using the **cobas**<sup>®</sup> BRAF Test.

**Table 6**  
**BRAF Homolog Plasmid Samples**

| Panel           |        | Composition by Volume  |                      |
|-----------------|--------|------------------------|----------------------|
| Name            | Member | Component 1            | Component 2          |
| BRAF Pseudogene | 1      | 95% BRAF Pseudogene    | 5% BRAF V600E Mutant |
|                 | 2      | 100% BRAF Pseudogene   | - - -                |
| ARAF            | 1      | 95% ARAF               | 5% BRAF V600E Mutant |
|                 | 2      | 100% ARAF              | - - -                |
| RAF1            | 1      | 95% RAF1               | 5% BRAF V600E Mutant |
|                 | 2      | 100% RAF1              | - - -                |
| Control         | 1      | 95% BRAF Wild-type     | 5% BRAF V600E Mutant |
|                 | 2      | 100% BRAF Wild-type    | - - -                |
|                 | 3      | 95% DNA Elution Buffer | 5% BRAF V600E Mutant |

None of the three BRAF homolog plasmids tested were detected by the **cobas**<sup>®</sup> BRAF Test when tested alone, indicating that the BRAF homolog plasmids do not cross-react with the test.

The BRAF V600E Mutant plasmid at 5% in the presence of 95% of the BRAF homolog plasmids gave the expected "Mutation Detected" result in all cases, indicating that the homolog plasmids did not interfere with detection of the BRAF V600E mutation.

### Skin-related Microorganisms

The following skin-related microorganisms were found to not cross react in the **cobas**<sup>®</sup> BRAF Test when added to a wild-type melanoma FFPET specimen at  $1 \times 10^6$  colony forming units (CFU) during the tissue lysis step:

1. *Staphylococcus epidermis*
2. *Staphylococcus aureus*
3. *Corynebacterium xerosis*
4. *Corynebacterium jeikeium*
5. *Corynebacterium minutissimum*
6. *Corynebacterium ulcerans*

The tested microorganisms also did not interfere with detection of an FFPET specimen with 8% BRAF V600E mutation when  $1 \times 10^6$  colony forming units were added during the tissue lysis step.

### Interference

Triglycerides ( $\leq 74$  mM, 2x CLSI recommended high concentration<sup>15</sup>), and hemoglobin ( $\leq 2$  mg/mL, 1x CLSI recommended high concentration<sup>15</sup>), did not interfere with the **cobas**<sup>®</sup> BRAF Test when the potential interfering substance was added to the lysis step during the specimen preparation procedure.

### Necrotic tissue

The ability of the **cobas**<sup>®</sup> BRAF Test to perform correctly when samples have high necrotic tissue content was tested using 27 V600E or WT melanoma FFPET specimens that contained from 10% to 95% necrotic tissue. Samples were selected based on their BRAF V600E mutation status, necrotic tissue content, and percent mutation. Of the 27 specimens selected, 11 were BRAF V600E mutant, and 16 were BRAF wild-type. The percent mutation ranged from 4% to 65%. The tumor content and percentage of necrotic tissue in each specimen was reviewed by a pathologist. Samples were run in duplicate using 1 lot of reagents. For the 11 BRAF V600E specimens, mutation detected results were obtained for all samples except one whose % mutation was below the threshold of detection (4%). The specimen with 95% necrotic tissue whose % mutation was 10% was correctly called mutation detected. Mutation not detected results were obtained for all wild-type specimens.

**Table 7**  
**Summary of cobas® BRAF Test Performance with High Necrotic Melanoma FFPET Specimens**

| Specimen | % Necrosis | Test Results (n = 2)                        |
|----------|------------|---------------------------------------------|
| V600E    | 15%        | Mutation Detected/Mutation Detected         |
|          | 15%        | Mutation Detected/Mutation Detected         |
|          | 20%        | Mutation Detected/Mutation Detected         |
|          | 25%        | Mutation Detected/Mutation Detected         |
|          | 25%        | Mutation Detected/Mutation Detected         |
|          | 30%        | Mutation Detected/Mutation Detected         |
|          | 30%        | Mutation not Detected/Mutation not Detected |
|          | 55%        | Mutation Detected/Mutation Detected         |
|          | 55%        | Mutation Detected/Mutation Detected         |
|          | 60%        | Mutation Detected/Mutation Detected         |
|          | 95%        | Mutation Detected/Mutation Detected         |

#### Melanin

The impact of high concentrations of endogenous melanin was evaluated using highly pigmented melanoma FFPET samples. A total of 41 unique FFPET melanoma tumor tissue specimens were selected based upon their level of pigmentation: 33 were highly pigmented, 3 were from African Americans and 5 were lightly pigmented for comparison. DNA was extracted from the tissue and melanin concentration was determined for each sample. A single replicate of the DNA stock from each of the two sections obtained from each of the 41 specimens was tested. Three specimens produced invalid results. One specimen produced a mutation not detected result but this specimen was determined to be below the limit of detection. The 3 specimens with "Invalid," results were used to prepare the recommended concentration of DNA for the test as well as two-fold, four-fold, and eight-fold dilutions of the recommended DNA input of 125 ng/PCR.

The resulting diluted DNA samples (containing a total of 125 ng, 61.5 ng, 31.25 ng, or 15.6 ng DNA in the 25 µL) were retested to determine if the corresponding reduction in melanin by dilution allowed valid results to be obtained. All three specimens when diluted 2-fold yielded the correct results.

**Table 8**  
**Summary of cobas® BRAF Test Performance with**  
**Pigmented Melanoma FFPE Specimens**

| Specimen ID | Dilution             | Melanin amount in Sample/PCR | Result                                  |
|-------------|----------------------|------------------------------|-----------------------------------------|
| <b>1</b>    | None (125 ng)        | 0.15 µg                      | Invalid/Invalid                         |
|             | Two-fold (62.5 ng)   | 0.08 µg                      | Mutation Detected/Mutation Detected     |
|             | Four-fold (31.3 ng)  | 0.04 µg                      | Mutation Detected/Mutation Detected     |
|             | Eight-fold (15.6 ng) | 0.02 µg                      | Mutation Detected/Mutation Detected     |
| <b>2</b>    | None (125 ng)        | 0.24 µg                      | Invalid/Invalid                         |
|             | Two-fold (62.5 ng)   | 0.12 µg                      | Mutation Detected/Mutation Detected     |
|             | Four-fold (31.3 ng)  | 0.06 µg                      | Mutation Detected/Mutation Not Detected |
|             | Eight-fold (15.6 ng) | 0.03 µg                      | Mutation Not Detected/Invalid           |
| <b>3</b>    | None (125 ng)        | 0.34 µg                      | Invalid/Invalid                         |
|             | Two-fold (62.5 ng)   | 0.17 µg                      | Mutation Detected/Mutation Detected     |
|             | Four-fold (31.3 ng)  | 0.08 µg                      | Mutation Detected/Mutation Detected     |
|             | Eight-fold (15.6 ng) | 0.04 µg                      | Mutation Detected/Mutation Detected     |

Results of testing the 17 V600 wild-type specimens showed that all of the samples were correctly assigned a "Mutation Not Detected" result with the exception of 2 highly pigmented samples which yielded false positive results.

#### Reproducibility

An external study was performed to assess the reproducibility of the **cobas®** BRAF Test across 3 external testing sites (2 operators per site), 3 reagent lots, and 5 non-consecutive testing days, with an 8-member panel of DNA samples derived from FFPE sections of malignant melanoma. This panel included both pigmented and non-pigmented samples and a range of percent tumor content and percent mutant alleles, including one sample at 4% (near the 5% limit of detection (LOD)). Of 94 runs, 92 (97.9%) were valid. Of 1442 samples tested, 2 samples (0.14%) gave invalid results. For all of the panel members except for the LOD samples, the correct call was made for 100% of valid tests, including samples panel members with 20% mutation, and two panel members determined to be highly pigmented. For the LOD panel member, the V600E mutation was detected in 90% (162/180) of samples. There were no false positives for any WT sample tested. Results by overall agreement are presented below.

**Table 9**  
**Overall Agreement Estimates by Panel Member in the**  
**cobas® BRAF Test Reproducibility Study**

| Panel Member                     | Number of Valid Tests | Agreement (%)   | 95% CI <sup>a</sup> for Agreement (%) |
|----------------------------------|-----------------------|-----------------|---------------------------------------|
| Wild-type-75% Tumor              | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |
| Wild-type-75% Tumor Pigmented    | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |
| V600E-5% Mutation                | 180                   | 90.0 (162/180)  | (84.7, 94.0)                          |
| V600E-20% Mutation               | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |
| V600E Mutant-50% Tumor           | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |
| V600E Mutant-50% Tumor Pigmented | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |
| V600E Mutant-75% Tumor           | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |
| V600E Mutant-90% Tumor           | 180                   | 100.0 (180/180) | (98.0, 100.0)                         |

Note: Results are included as agreement when valid test of Mutant Type panel member has a result of "Mutation Detected" or when a valid test of a Wild-type panel member has a result of "Mutation Not Detected".

<sup>a</sup> 95% CI=95% exact binomial confidence interval.

Across all components of variance (lot, site, operator, day, within-run), the CV (%) for the mutant and wild-type Cts were calculated and was <3% and <1.8%, respectively for all panel members. The CV(%) for the external controls was ≤ 2.0%.

#### Repeatability

To evaluate the repeatability of the **cobas®** BRAF Test, a separate internal study was conducted. Duplicate results were obtained on five different melanoma FFPE specimens tested on four different days by two operators, using two different reagent lots and two **cobas®** 4800 instruments. Four BRAF V600E-mutant specimens, two with tumor content less than 35%, two with mutation percentages less than 12% (~2X of the analytical sensitivity of the **cobas®** BRAF Test of 5% mutation detection), and one Wild-type specimen were selected for this study. On each of the four days, each of two operators tested four sections from each of the 5 FFPE melanoma specimens, two sections were tested per lot of DNA Specimen Preparation Kit and **cobas®** BRAF Test kit. A total of 32 replicates were evaluated per sample. Repeatability was considered acceptable if at least 95% of the calls corresponded to sequencing results for the specimens. A single replicate of one BRAF V600E mutant specimen (10% mutation) and a single replicate of another BRAF V600E mutant specimen (10% mutation) had results of "Mutation Not Detected." All other replicates for those specimens and all replicates for the remaining three specimens matched the expected results, corresponding to a correct call accuracy of 98.75% across the entire study.

**Table 10**  
**Repeatability of the cobas® BRAF Test**

| Panel Member (% mutation) | % Tumor Content <sup>a</sup> | Tumor Stage | Total no. replicates tested | Total no incorrect calls | % accuracy |
|---------------------------|------------------------------|-------------|-----------------------------|--------------------------|------------|
| V600E (10%)               | 60% / 55%                    | IV          | 32                          | 1                        | 96.9       |
| V600E (12%)               | 40% / 35%                    | IIIB        | 32                          | 0                        | 100        |
| V600E (10%)               | 30% / 30%                    | IV          | 32                          | 1                        | 96.9       |
| V600E (17%)               | 30% / 35%                    | II          | 32                          | 0                        | 100        |
| WT                        | 60% / 60%                    | IV          | 32                          | 0                        | 100        |

<sup>a</sup> Tumor content of the specimen was assessed by examining the first and last of twelve adjacent 5-µm sections of each specimen by a pathologist. The tumor content of both the first and the last section is shown (for example, 95% / 95%).

To evaluate the performance of the **cobas**<sup>®</sup> BRAF Test when compared to 2X bi-directional sequencing, 596 consecutive patients screened for the Phase III trial were identified for whom clinical, demographic, and Sanger sequencing data were collected. Of these cases, 94 were ineligible because of missing inclusion criteria, 4 cases were without pathology review, 2 cases had invalid **cobas**<sup>®</sup> BRAF Test results and 47 specimens had invalid Sanger sequencing results leaving 449 evaluable cases. The agreement analysis between the **cobas**<sup>®</sup> BRAF Test results and Sanger sequencing results for the detection of the V600E mutation is shown in Table 11 below. The Positive Percent Agreement (PPA) with Sanger sequencing was 97.3% (216/222), and the Negative Percent Agreement (NPA) was 84.6% (192/227), with an overall Percent Agreement of 90.9%. There were a total of 35 mutations detected by the **cobas**<sup>®</sup> BRAF Test which were not identified as V600E mutations by Sanger sequencing. Eight (8) of these were wild type, 25 were V600K and 2 were other codon 600 mutations by Sanger sequencing. Additionally, 6 specimens were identified as Mutation Not Detected by the **cobas**<sup>®</sup> BRAF Test but were identified as V600E by Sanger sequencing. The cross-reactivity of the **cobas**<sup>®</sup> BRAF Test for V600K was 66% (25/38).

**Table 11**  
***cobas*<sup>®</sup> BRAF Test vs. Sanger Sequencing for Specimens from Phase III Study\***

| cobas® BRAF<br>Test Result          | Sanger Sequencing (Reference Method) |                                  |                                       |        |       |         |                  | Total |
|-------------------------------------|--------------------------------------|----------------------------------|---------------------------------------|--------|-------|---------|------------------|-------|
|                                     | BRAF V600E<br>Mutation<br>Detected   | BRAF V600E Mutation Not Detected |                                       |        |       |         |                  |       |
|                                     |                                      | V600E                            | V600K                                 | V600E2 | V600R | V600D** | V600<br>Other*** |       |
| Mutation<br>Detected                | 216                                  | 25                               | 1                                     | 0      | 1     | 0       | 8                | 251   |
| Mutation Not<br>Detected            | 6                                    | 13                               | 12                                    | 2      | 0     | 1       | 164              | 198   |
| Total                               | 222                                  | 38                               | 13                                    | 2      | 1     | 1       | 172              | 449   |
| Positive Percent Agreement (95% CI) |                                      |                                  | 216/222 X 100% = 97.3% (94.2%, 98.8%) |        |       |         |                  |       |
| Negative Percent Agreement (95% CI) |                                      |                                  | 192/227 X 100% = 84.6% (79.3%, 88.7%) |        |       |         |                  |       |
| Overall Percent Agreement           |                                      |                                  | 408/449 X 100% = 90.9% (87.8%, 93.2%) |        |       |         |                  |       |

\*Sanger sequencing has a limit of detection of approximately 20% mutant alleles in FFPE specimens.<sup>16,17,18,19</sup> Therefore, Sanger sequencing cannot be adequately used to confirm mutation status at lower percentages of mutant alleles. Consistent with this, in an exploratory analysis, some samples that were negative by Sanger sequencing and positive by the **cobas**<sup>®</sup> BRAF Test tested positive by a third method. The **cobas**<sup>®</sup> BRAF Test has a validated limit of detection in FFPE of 5% mutant alleles.

\*\*V600D variant (GTG>GAC)

\*\*\*Mutation not specified in the protocol (ACA insertion immediately before Codon 600)

The estimated prevalence of the V600E mutation in the Phase III clinical trial was 50 to 55% based on results with the **cobas**<sup>®</sup> BRAF Test. This is consistent with the prevalence of V600E in melanoma patients as reported in literature.<sup>3</sup>

All of the patients in the phase III study NO25026 (BRIM3) sponsored by Hoffmann-LaRoche were selected using the **cobas**<sup>®</sup> BRAF Test. Enrollment in the study was limited to patients whose melanoma tissue was "Mutation Detected" by the test. Therefore it is not known whether patients whose result is "Mutation Not Detected" or "No Mutation Detected" by the **cobas**<sup>®</sup> BRAF Test will benefit from ZELBORAF<sup>®</sup> treatment.

ZELBORAF<sup>®</sup> (vemurafenib) Clinical Efficacy<sup>7</sup> (refer to Drugs@FDA for the most recent therapeutic product labeling)

The **cobas<sup>®</sup>** BRAF Test was used as a companion test for selecting patients for treatment with ZELBORAF<sup>®</sup>. The clinical safety and effectiveness of ZELBORAF<sup>®</sup> was demonstrated in the NO25026 study (BRIM3), an international, randomized, open-label, controlled, multicenter, Phase III study in previously untreated patients with unresectable stage IIIC or stage IV melanoma with V600E BRAF mutation to evaluate the efficacy of ZELBORAF<sup>®</sup> versus dacarbazine. FFFPET samples from all melanoma patients being considered for treatment were tested with the **cobas<sup>®</sup>** BRAF Test. Patients with a "Mutation Detected" test result were eligible for enrollment in the drug trials if they met other eligibility criteria. Patients with a "Mutation Not Detected" test result were ineligible for drug trial enrollment. The study was conducted at approximately 104 sites (22 centers in the US).

The trial enrolled 675 patients; 337 were allocated to receive vemurafenib and 338 to receive dacarbazine. The major efficacy outcome measures of the trial were overall survival (OS) and investigator-assessed progression-free survival (PFS). Other outcome measures included confirmed investigator-assessed best overall response rate.

Baseline characteristics were balanced between treatment groups. Most patients were male (56%) and Caucasian (99%), the median age was 54 years (24% were ≥ 65 years), all patients had ECOG performance status of 0 or 1, and the majority of patients had metastatic disease (95%).

**Table 12**  
**Efficacy of Vemurafenib in Treatment-Naïve Patients with BRAFV600E Mutation-Positive Melanoma<sup>a</sup>**

|                                                                 | <b>Vemurafenib<br/>(N=337)</b>    | <b>Dacarbazine<br/>(N=338)</b> | <b>p-value<sup>d</sup></b> |
|-----------------------------------------------------------------|-----------------------------------|--------------------------------|----------------------------|
| Overall Survival                                                |                                   |                                |                            |
| Number of Deaths                                                | 78 (23%)                          | 121 (36%)                      |                            |
| Hazard Ratio<br>(95% CI) <sup>b</sup>                           | 0.44<br>(0.33, 0.59)              |                                | <0.0001                    |
| Median Survival (months)<br>(95 % CI) <sup>c</sup>              | Not Reached<br>(9.6, Not Reached) | 7.9<br>(7.3, 9.6)              | -                          |
| Median Follow-up (months)<br>(range)                            | 6.2<br>(0.4, 13.9)                | 4.5<br>(<0.1, 11.7)            |                            |
| Progression-free survival Hazard<br>Ratio (95% CI) <sup>b</sup> | 0.26<br>(0.20, 0.33)              |                                | <0.0001                    |
| Median PFS (months) <sup>c</sup>                                | 5.3<br>(4.9, 6.6)                 | 1.6<br>(1.6, 1.7)              | -                          |


<sup>a</sup>As detected by the **cobas<sup>®</sup>** BRAF Test

<sup>b</sup>Hazard ratio estimated using Cox model; a hazard ratio of < 1 favors vemurafenib

<sup>c</sup>Kaplan-Meier estimate

<sup>d</sup>Unstratified log-rank test

**Figure 2**  
**Kaplan-Meier Curves of Overall Survival – Treatment Naïve Patients**



The confirmed, investigator-assessed best overall response rate was 48.4% (95% CI: 41.6%, 55.2%) in the ZELBORAF<sup>®</sup> arm compared to 5.5% (95% CI: 2.8%, 9.3%) in the dacarbazine arm.

COTELLIC<sup>®</sup> (cobimetinib) Clinical Efficacy<sup>8,9</sup>  
(refer to Drugs@FDA for the most recent therapeutic product labeling)

COTELLIC<sup>®</sup>, a MEK inhibitor, was tested in a clinical trial in combination with ZELBORAF<sup>®</sup> compared to ZELBORAF<sup>®</sup> plus placebo. The **cobas**<sup>®</sup> BRAF Test was used to determine eligibility for enrollment of patients in this clinical trial. The safety and efficacy of the combination of COTELLIC<sup>®</sup> and ZELBORAF<sup>®</sup> was established in a multicenter, randomized (1:1), double-blinded, placebo-controlled trial conducted in 495 patients with previously untreated, BRAF V600 mutation-positive, unresectable or metastatic, melanoma. The major efficacy outcome was investigator-assessed progression-free survival (PFS) per RECIST v1.1. Additional efficacy outcomes were investigator-assessed confirmed objective response rate (ORR), overall survival (OS), PFS as assessed by blinded independent central review, and duration of response (DOR).

Baseline characteristics were balanced between treatment groups. Most patients were male (58%) and Caucasian (93%), the median age was 55 years, 72% patients had ECOG performance status of 0, and 60% of patients had stage M1c disease.

FFPET samples from all patients being considered for treatment were tested with the **cobas**<sup>®</sup> BRAF Test. Patients with a "Mutation Detected" result were eligible for enrollment in the trial if they met other eligibility criteria. Patients with a "No Mutation Detected" result were ineligible for enrollment in the trial. The trial included patients with BRAF V600K mutation as detected by the **cobas**<sup>®</sup> BRAF Test, demonstrating therapeutic product safety and efficacy in the detected portion of the patient population with tumors containing V600K.

Efficacy Results from the Trial are shown below in Table 13 and Figure 3:

**Table 13**  
**Efficacy of Cobimetinib in Combination with Vemurafenib in Patients with BRAF Mutation-Positive Melanoma<sup>a</sup>**

|                                                               | Cobimetinib +<br>Vemurafenib<br>(N=247) | Placebo +<br>Vemurafenib<br>(N=248) | p-value               |
|---------------------------------------------------------------|-----------------------------------------|-------------------------------------|-----------------------|
| Progression-free survival (Investigator-assessed)             |                                         |                                     |                       |
| Number of events (%)                                          | 143 (58%)                               | 180 (73%)                           |                       |
| Progression                                                   | 131                                     | 169                                 |                       |
| Death                                                         | 12                                      | 11                                  |                       |
| Median PFS (months)<br>(95% CI)                               | 12.3<br>(9.5, 13.4)                     | 7.2<br>(5.6, 7.5)                   |                       |
| Hazard Ratio (95% CI) <sup>b</sup>                            | 0.56 (0.45, 0.70)                       |                                     | <0.001 <sup>d</sup>   |
| Overall Survival                                              |                                         |                                     |                       |
| Number of Deaths (%)                                          | 79 (32%)                                | 109 (44%)                           |                       |
| Median Survival (months)<br>(95 % CI) <sup>c</sup>            | Not estimable<br>(20.7, Not estimable)  | 17.0<br>(15.0, Not estimable)       | -                     |
| Hazard Ratio<br>(95% CI) <sup>b</sup>                         | 0.63<br>(0.47, 0.85)                    |                                     | 0.0019 <sup>d,e</sup> |
| Objective Response Rate                                       |                                         |                                     |                       |
| Objective Response Rate<br>(95 % CI) <sup>c</sup>             | 70%<br>(64%, 75%)                       | 50%<br>(44%, 56%)                   | <0.001                |
| Complete Response                                             | 16%                                     | 10%                                 |                       |
| Partial Response                                              | 54%                                     | 40%                                 |                       |
| Median Duration of Response,<br>months (95 % CI) <sup>c</sup> | 13.0<br>(11.1, 16.6)                    | 9.2<br>(7.5, 12.8)                  | -                     |

<sup>a</sup>As detected by the **cobas<sup>®</sup>** BRAF Test


<sup>b</sup>Hazard ratio estimated using Cox model; a hazard ratio of < 1 favors cobimetinib + vemurafenib

<sup>c</sup>Kaplan-Meier estimate

<sup>d</sup>Stratified log-rank test

<sup>e</sup>Statistical significance depending on the comparison to the allocated alpha of 0.019 for this interim analysis

**Figure 3**  
**Kaplan-Meier Curves of Overall Survival**



Available tumor samples from randomized patients were retrospectively analyzed using next generation sequencing to further classify the BRAF mutations as V600E or V600K; test results were obtained on 81% of randomized patients (400/495). Among those patients for whom next generation sequencing was successfully performed, 56 out of 400 (14%) patients had tumors with BRAF V600K mutations, and the remaining patients had tumors with BRAF V600E mutations. The 56 tumors that were retrospectively found to have the BRAF V600K mutation had mutation frequencies between 5.1 and 36.6% in this analysis. A trend favoring the cobimetinib with vemurafenib arm was observed in exploratory subgroup analyses of PFS, OS, and ORR for the BRAF V600 mutation subtypes in the 81% of patients in this trial where BRAF V600 mutation type was determined.

## REFERENCES

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417:949-54.
2. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta*. 2007;1773:1263-84.
3. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med*. 2005;353:2135-47.
4. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. *Nat Genet*. 2003;33:19-20.
5. COSMIC database (<http://www.sanger.ac.uk/perl/genetics/CGP/cosmic>), Release 52 (March 2011).
6. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med*. 2010;363:809-19.
7. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*. 2011;364:2507-16.
8. Ascierto PA, McArthur GA, Dréno B, et al. Overall survival with cobimetinib combined with vemurafenib in advanced BRAFV600-mutated melanoma: updated efficacy results from the phase 3, randomised coBRIM study. *Lancet Oncol*. 2016;17:1248-60.
9. COTELLIC® (cobimetinib) U.S. package insert, Version 2.1, 2016.
10. Siroy AE, Boland GM, Milton DR, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. *J Invest Dermatol*. 2015;135:508-15.
11. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. *Gene*. 1990;93:125-8.
12. Chosewood LC, Wilson DE. Biosafety and microbiological and biomedical laboratories. HHS Publication Fifth edition. (CDC) 21-1112. 2009.
13. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4;Wayne, PA;CLSI, 2014.
14. International Air Transport Association. Dangerous goods regulations, 52nd Edition. 2011.
15. Clinical and Laboratory Standards Institute (CLSI). Interference testing in clinical chemistry. Approved Guideline-Second Editio. CLSI DSocument EP7-A2 Appendix D;Wayne, PA;CLSI, 2005.
16. Querings S, Atmüller J, Ansén S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. *PLoS One*. 2011;6: e19601.doi:10.1371/journal.pone. 0019601.
17. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. *J Mol Diagn*. 2009;11:140-7.
18. Tsiatis AC, Nolrris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. *J Mol Diagn*. 2010;12:425-32.
19. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. *J Mol Diagn*. 2005;7:413-21.

| Document Revision Information |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Doc Rev. 6.0<br>12/2016       | <p>Updated <b>INTENDED USE</b> and <b>SUMMARY AND EXPLANATION OF TEST</b> sections.</p> <p>Added <b>Cobimetinib Clinical Efficacy</b> section.</p> <p>Updated hazard warnings.</p> <p>Updated descriptions of the harmonized symbol page at the end of the package insert.</p> <p>Updated trademarks and patents section to reference online resource only.</p> <p>Added Roche web address <a href="http://www.roche.com">www.roche.com</a>.</p> <p>Please contact your local Roche Representative if you have any questions.</p> |

Manufactured in the United States



Roche Diagnostics GmbH  
Sandhofer Strasse 116  
68305 Mannheim, Germany  
[www.roche.com](http://www.roche.com)



Distributed by

Roche Diagnostics  
9115 Hague Road  
Indianapolis, IN 46250-0457 USA  
(For Technical Assistance call the  
Roche Response Center  
toll free: 1-800-526-1247)

#### Trademarks and Patents

See <http://www.roche-diagnostics.us/patents>

©2016 Roche Molecular Systems, Inc.

12/2016

05952590001-06

Doc Rev. 6.0

The following symbols are now used in labeling for Roche PCR diagnostic products.



Ancillary Software



*In Vitro* Diagnostic Medical Device



Authorized Representative  
in the European community



For IVD Performance  
Evaluation Only



Barcode Data Sheet



Lower Limit of Assigned Range



Batch code



Manufacturer



Biological Risks



Store in the dark



Catalogue number



Temperature Limit



Consult instructions for use



Test Definition File



Contains Sufficient for <n> tests



Upper Limit of Assigned Range



Contents of kit



Use-by date



Distributed by

US Customer Technical Support 1-800-526-1247